|
EP2670848B1
(en)
|
2011-02-06 |
2016-02-03 |
Yeda Research and Development Co. Ltd |
Affinity maturated t cell receptors and use thereof
|
|
ES2841274T3
(es)
*
|
2014-08-04 |
2021-07-07 |
Hutchinson Fred Cancer Res |
Inmunoterapia con células T específica para WT-1
|
|
GB201417803D0
(en)
|
2014-10-08 |
2014-11-19 |
Adaptimmune Ltd |
T cell receptors
|
|
EP3067366A1
(en)
|
2015-03-13 |
2016-09-14 |
Max-Delbrück-Centrum Für Molekulare Medizin |
Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
|
|
CN108290940B
(zh)
*
|
2015-10-01 |
2021-12-07 |
圣拉斐尔医院有限公司 |
Tcr及其用途
|
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520544D0
(en)
*
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
|
EP3219800A1
(en)
|
2016-03-15 |
2017-09-20 |
Max-Delbrück-Centrum Für Molekulare Medizin |
A transposon-based transfection system for primary cells
|
|
CN106749620B
(zh)
*
|
2016-03-29 |
2020-09-25 |
广东香雪精准医疗技术有限公司 |
识别mage-a1抗原短肽的t细胞受体
|
|
MX2018012318A
(es)
|
2016-04-08 |
2019-07-04 |
Immunocore Ltd |
Receptores de celulas t.
|
|
CN106084042B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗MAGEA1的全分子IgG抗体及其应用
|
|
WO2018056897A1
(en)
*
|
2016-09-23 |
2018-03-29 |
Lion Tcr Pte. Ltd. |
An hbv antigen specific binding molecules and fragments thereof
|
|
MD3551221T2
(ro)
|
2016-12-08 |
2022-04-30 |
Immatics Biotechnologies Gmbh |
Noi receptori de celule T și imunoterapie cu utilizarea acestora
|
|
DE102016123847B3
(de)
|
2016-12-08 |
2018-04-05 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
CN108250289B
(zh)
*
|
2016-12-28 |
2021-10-08 |
香雪生命科学技术(广东)有限公司 |
源自于mage b6的肿瘤抗原短肽
|
|
AU2018234830B2
(en)
*
|
2017-03-15 |
2023-03-02 |
Fred Hutchinson Cancer Center |
High affinity MAGE-A1-specific TCRs and uses thereof
|
|
CN108929378B
(zh)
*
|
2017-05-22 |
2021-04-23 |
香雪生命科学技术(广东)有限公司 |
一种识别prame抗原的t细胞受体及编码该受体的核酸
|
|
US11517591B2
(en)
|
2017-09-01 |
2022-12-06 |
Dana-Farber Cancer Institute, Inc. |
Immunogenic peptides specific to BCMA and TACI antigens
|
|
GB2613715B
(en)
*
|
2019-02-20 |
2023-12-06 |
Fred Hutchinson Cancer Center |
Binding proteins specific for RAS neoantigens and uses thereof
|
|
EP3941938A1
(en)
|
2019-03-06 |
2022-01-26 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
TWI850360B
(zh)
|
2019-04-04 |
2024-08-01 |
德商梅迪基因免疫治療公司 |
黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
JP7461452B2
(ja)
*
|
2019-07-09 |
2024-04-03 |
メディジーン イミュノテラピーズ ゲーエムベーハー |
Magea10特異的t細胞受容体およびその使用
|
|
GB201915282D0
(en)
*
|
2019-10-22 |
2019-12-04 |
Immunocore Ltd |
Specific binding molecules
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
CN113684258B
(zh)
*
|
2020-05-18 |
2024-08-20 |
上海赛比曼生物科技有限公司 |
用于检测鼠源tcr转基因拷贝数的试剂盒及方法
|
|
EP4171587A4
(en)
*
|
2020-06-25 |
2024-07-24 |
The Methodist Hospital |
Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
|
|
IL276599A
(en)
*
|
2020-08-09 |
2022-03-01 |
Yeda Res & Dev |
T cell receptor unique to mage-a1 and its uses
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CN112279908B
(zh)
*
|
2020-10-23 |
2024-03-19 |
魏放 |
识别ebv抗原短肽的t细胞受体及其应用
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用FLT3L—Fc融合蛋白之方法
|
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP2024541979A
(ja)
|
2021-10-29 |
2024-11-13 |
ギリアード サイエンシーズ, インコーポレイテッド |
Cd73化合物
|
|
EP4430402A1
(en)
|
2021-11-09 |
2024-09-18 |
T-Knife GmbH |
Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
|
|
KR20240125012A
(ko)
|
2021-12-22 |
2024-08-19 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
|
DK4245756T3
(da)
|
2022-03-17 |
2024-10-21 |
Gilead Sciences Inc |
Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf
|
|
IL316058A
(en)
|
2022-04-21 |
2024-11-01 |
Gilead Sciences Inc |
Compounds modulate KRAS G12D
|
|
CN116693656A
(zh)
*
|
2022-04-27 |
2023-09-05 |
恒瑞源正(广州)生物科技有限公司 |
Mage-a1特异性t细胞受体及其用途
|
|
CR20240570A
(es)
|
2022-07-01 |
2025-03-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
TW202417476A
(zh)
|
2022-08-18 |
2024-05-01 |
英商英美偌科有限公司 |
T細胞受體及其融合蛋白
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
US20240383922A1
(en)
|
2023-04-11 |
2024-11-21 |
Gilead Sciences, Inc. |
KRAS Modulating Compounds
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025027088A1
(en)
|
2023-07-31 |
2025-02-06 |
T-Knife Gmbh |
An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025027087A1
(en)
|
2023-07-31 |
2025-02-06 |
T-Knife Gmbh |
A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025045752A1
(en)
|
2023-08-25 |
2025-03-06 |
T-Knife Gmbh |
Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096983A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Board Of Regents, The University Of Texas System |
Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025146286A1
(en)
|
2024-01-04 |
2025-07-10 |
Immunoscape Pte. Ltd. |
Human t cell receptors and uses thereof
|
|
WO2025190565A1
(en)
|
2024-03-13 |
2025-09-18 |
T-Knife Gmbh |
A chimeric programmed cell death protein 1 receptor
|
|
WO2025191067A1
(en)
|
2024-03-13 |
2025-09-18 |
T-Knife Gmbh |
A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with ig and itim domains (tigit) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|